Enzalutamide in metastatic prostate cancer before chemotherapy

Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury, Ian Davis, Johann S De Bono, Christopher P Evans, Karim Fizazi, Anthony Michael Joshua, Choung-Soo Kim, Go Kimura, Paul N Mainwaring, Harry Mansbach, Kurt MillerSarah B Noonberg, Frank Perabo, De Phung, Fred Saad, Howard I Scher, Mary-Ellen Taplin, Peter M Venner, Bertrand Tombal

Research output: Contribution to journalArticleResearchpeer-review

1375 Citations (Scopus)


Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.
Original languageEnglish
Pages (from-to)424 - 433
Number of pages10
JournalThe New England Journal of Medicine
Issue number5
Publication statusPublished - 2014

Cite this